Intercell's Ixiaro JE vacc recommended for EU approval

US biotechnology firm Epix Pharmaceuticals has sold the US, Canadian and Australian rights for its blood pool magnetic resonance angiography  agent Vasovist (gadofosveset trisodium) to Lantheus Medical  Imaging for $28.0 million. Epix will continue to own European and  certain other non-US rights for the imaging agent, enabling it to pursue  further monetization of the rights. The Massachusetts-based company  is trying to restructure its debts to avoid filing for bankruptcy and  will pay $10.5 million of the cash proceeds from the sale to its old  marketing partner Bayer to cover the German firm's development costs.  The two companies terminated their Vasovist accord on February 28.